Overview

Open-Label Study to Assess Meplazumab in Adult Patients Diagnosed with Plasmodium Falciparum

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2025-10-09
Target enrollment:
Participant gender:
Summary
This phase 2a open-label study to assess Meplazumab in adult patients diagnosed with Plasmodium falciparum
Phase:
PHASE2
Details
Lead Sponsor:
Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd
Treatments:
Injections
meplazumab